Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1630 - Practical effectiveness efficacy and safety of nivolumab for advanced non-small cell lung cancer: a retrospective multicenter analysis

Date

09 Sep 2017

Session

Poster display session

Topics

Cancers in Adolescents and Young Adults (AYA);  Immunotherapy;  Non-Small Cell Lung Cancer

Presenters

Keigo Kobayashi

Citation

Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380

Authors

K. Kobayashi1, I. Nakachi2, K. Naoki1, Y. Oyamada3, M. Nakamura4, T. Inoue5, H. Tateno6, F. Sakamaki7, K. Sayama8, T. Terashima9, H. Koh10, D. Arai2, H. Yasuda1, I. Kawada1, K. Soejima1, T. Betsuyaku1

Author affiliations

  • 1 Division Of Pulmonary Medicine, Keio University, 160-8582 - Tokyo/JP
  • 2 Pulmonary Division, Internal Medicine, Saiseikai Utsunomiya Hospital, 321-0974 - Utsunomiya/JP
  • 3 Pulmonary Division, Internal Medicine, National Hospital Organization Tokyo Medical Center, Tokyo/JP
  • 4 Pulmonary Division, Internal Medicine, Tokyo Saiseikai Central Hospital, Tokyo/JP
  • 5 Pulmonary Division, Internal Medicine, Sano Kousei General Hospital, Sano/JP
  • 6 Pulmonary Division, Internal Medicine, Saitama City Hospital, Saitama/JP
  • 7 Pulmonary Division, Internal Medicine, Tokai University Hachioji Hospital, Hachiouji/JP
  • 8 Pulmonary Division, Internal Medicine, Kawasaki Municipal Hospital, Kawasaki/JP
  • 9 Pulmonary Division, Internal Medicine, Tokyo Dental College Ichikawa General Hospital, Ichikawa/JP
  • 10 Pulmonary Division, Internal Medicine, Tachikawa Hospital, Tachikawa/JP
More

Resources

Abstract 1630

Background

Nivolumab, an immune checkpoint inhibitor, is now a standard treatment for previously treated advanced non-small cell lung cancer. We aimed to evaluate the real-world efficacy and safety of nivolumab in a non-selective population and identify clinical characteristics that influence efficacy.

Methods

One hundred and forty-two patients with previously treated advanced non-small cell lung cancer who were administered nivolumab at Keio University and affiliated hospitals (in Japan) between January and July 2016 were enrolled. Treatment responses and adverse events were retrospectively reviewed and clinical characteristics associated with nivolumab responses were evaluated using univariate and stratified analyses and the Cochran-Mantel-Haenszel test.

Results

The objective response rate was 17.0%, while the proportion of patients with adverse events of any grade was 45.0%. Clinical characteristics such as age, sex, Eastern Cooperative Oncology Group performance status, histological type, presence or absence of central nervous system metastases, smoking status, and the number of previous lines of treatment, were not related to efficacy. However, EGFR/ALK mutation status was inversely associated with treatment response (P < 0.05). Prior radiotherapy also exhibited a positive association with treatment response (P = 0.012). Although no significant difference was observed between current/ex-smokers and non-smokers (P = > 0.05), a subgroup analysis revealed smoking status in pack-years to be significantly higher in responders than non-responders (P < 0.05). Nivolumab is effective and safe regardless of age or the number of previous lines of treatment.

Conclusions

The objective response rate and adverse event profiles were comparable to those observed in previous clinical trials. An EGFR/ALK mutation-negative status and prior radiotherapy are key clinical characteristics that are statistically associated with a positive treatment response. Our findings may aid in the efficient immunotherapeutic management of advanced non-small cell lung cancer.

We will add other measurements of the treatment activity such as progression-free survival by the congress.

Clinical trial identification

Legal entity responsible for the study

Keio University

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.